Volume 25, No 3, Mar 2015

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 25 Issue 3, March 2015: 269-270

RESEARCH HIGHLIGHTS

Personalized one-two punches for lung cancer

Hannah A Scarborough^1,2, Paul A Bunn Jr³ and James DeGregori^1,2,3

¹Program in Molecular Biology, University of Colorado Cancer Center, Aurora, CO 80045, USA
²Department of Biochemistry and Molecular Genetics, University of Colorado Cancer Center, Aurora, CO 80045, USA
³Department of Medicine, School of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA Correspondence: James DeGregori,(james.degregori@ucdenver.edu)

Discovery of individualized therapies to address resistance to tyrosine kinase inhibitors (TKIs) has been hampered by the inability to test drug combinations on patient samples before and after TKI resistance. A recent study published in Science by Crystal et al. describes a methodology for pharmacological screening using a panel of 76 targeted agents and cell lines made directly from patient biopsies.

10.1038/cr.2014.168

FULL TEXT | PDF

Browse 1902